The industry and healthcare professionals place great importance on transparency, including in their own relationships. In Luxembourg, for the innovative pharmaceutical industry, these relationships are regulated by our code of ethics. However, in order to move towards greater transparency of these interactions, a central, common and publicly accessible transparency platform was developed in 2015 by the industry in close collaboration with several associations of healthcare professionals.
Companies that are members publish, on a voluntary basis, the incentives and benefits they have made towards healthcare professionals or organizations.
Integrity and independence of healthcare professionals are central
As crucial as it is, the relationship with the pharmaceutical industry cannot affect the independence of your healthcare professional or organization. To ensure this independence, member companies originally took the initiative to make their relationships with healthcare professionals and organizations transparent.
The integrity of your healthcare professional's decision to start, continue or stop a specific treatment is one of the pillars of our healthcare system. In recent years, society has shown increasing interest in the nature of the relationships between the pharmaceutical or medical device industry and healthcare stakeholders: the public is demanding more transparency and confirmation that these relationships do not negatively impact treatment decisions and that a healthcare professional's motive for prescribing a drug or medical device is based solely on clinical data and is intended to ensure the best possible patient care.
Premiums and Benefits
What is made public by name on this report?
Fees, payments and reimbursements for services and consultancy to healthcare professionals, healthcare organizations or patient organizations.
Contributions to the costs of organizing or participating in scientific events (registration fees, travel and accommodation expenses, sponsorship agreements) granted to healthcare professionals, healthcare organizations or patient organizations.
Donations and grants that support health care, awarded to health care organizations.
Financial or other support to patient organizations.
Companies are obliged to inform recipients of premiums and benefits about the processing of their data in advance. In case of refusal, the premiums and benefits are shared in an aggregated way.
What is made public in aggregate?
Incentives and benefits granted in the context of scientific research are made public in aggregate, i.e. without mentioning the identity of the healthcare professionals or organizations concerned. This includes bonuses and benefits granted in the context of clinical trials.
When and for how long?
Bonuses and benefits are made public at the end of June following the calendar year in which they were awarded.
Interested in becoming a partner?
To benefit from all of our services, more particularly :
- Participate in committees and commissions, in the different working groups
- Free access to our intranet
- Profit of the organizations networh: exchangres between experts, invitation to formations and exclusive meetings (economical, scientific, industrial, social, legal, RSE, parlementary, european, communication…)
- Being represented and being defended in front of institutions and the public, see the image of drug producing companies valued.
for more detailed information about the adhesion steps, please, contact us by mail email@example.com .